2023-07-29 21:49:00
The Medicines and Health Products Safety Agency reports a supply tension concerning the Ixiaro vaccine (Valneva laboratory). This vaccine is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants over 2 months of age. The administration of Ixiaro should be considered in subjects exposed to a risk of infection with the virus during travel or in the course of their professional activity.
French units are reserved for the town channel.Exceptional availability and transitory treatment of the specialty Ixiaro, an injectable suspension initially intended for the Belgian, Luxembourg and Dutch markets with international vaccination centers and other healthcare establishments from July 31, 2023. The composition, dosage, specifications and mode of use of the specialty IXIARO®, suspension for injection, are exactly the same as those of the specialty intended for the French marketThe date of Normal handover is estimated for September 2023.
In order to secure the situation in France as much as possible and to preserve available stocks, the sale and export of the medicinal product by wholesale distributors abroad is prohibited from the publication of this information sheet on the site of the National Agency for the Safety of Medicines and Health Products (ANSM), pursuant to Public Health Law 2016-41 published in the Official Journal on January 27, 2016 and the provisions of Articles L.5121-30 and L.5124 -17-3 of the Public Health Code. This measure prohibiting sales outside the national territory, or to wholesale distributors for export, must be applied and respected until the normal availability of the medicinal product, allowing a continuous and appropriate supply of the national market.
Source: National Agency for Medicines and Health Products (ANSM).
1690668746
#Ixairo #Vaccine #Supply #Voltage